EUROPE DIGITAL GENOME MARKET FORECAST 2021-2028

The Europe digital genome market is anticipated to register a CAGR of 9.16%, over the forecast period of 2021 to 2028. Leading factors driving the region’s market growth include, private and government funding for genome sequencing, the launch of innovative technologies for genome projects, and the increasing number of genome researches conducted. 

europe-digital-genome-market

The Europe digital genome market growth is assessed by evaluating Germany, Poland, Russia, Belgium, the United Kingdom, France, Italy, and the rest of Europe. In December 2018, 100,000 Genome Projects (100KGP) were completed in the United Kingdom. The project was launched by the country’s government, aiming at whole-genome sequencing of National Health Service (NHS) patients suffering from infectious diseases, cancer, and rare disease. Moreover, the United Kingdom’s government significantly contributes towards promoting advanced technologies, as well. Collaborative research and partnerships are also among the country’s most widespread and prominent trends. For instance, Illumina and Genomics England partnered in January 2020, in order to deliver whole-genome sequencing for England’s NHS Genomic Medicine Service.

In June 2016, the government of France invested nearly $760.8 million for programs associated with genomics and personalized medicine. The plans intend to enhance the diagnosis and prevention of diseases across the nation. Additionally, the chief areas targeted by French biotechnology companies, in terms of therapeutics and medicines, entail neurology, oncology, and infectious diseases. Therefore, these factors are projected to supplement the market growth in Europe over the forecast years.

F. Hoffman-La Roche Ltd, headquartered in Basel, Switzerland, is a healthcare company that develops and markets innovative diagnostic and therapeutic products. It also researches and manufactures pharmaceutical products across various therapeutic areas, such as, immunology, oncology, infectious disease, neuroscience, and ophthalmology. The company provides clinical chemistry, immunoassays, hematology and hemostasis products, and urinalysis products, among others.

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INCREASING FUNDING BY THE MANUFACTURERS AND GOVERNMENTS IN GENOMICS
      2. ADVANCEMENTS IN TECHNOLOGY
      3. SURGING PREVALENCE OF CHRONIC DISEASES
    2. KEY RESTRAINTS
      1. RISKS ASSOCIATED WITH SECURITY ISSUE OF DIGITAL GENOME
      2. LACK OF PROFESSIONALS WITH ADEQUATE KNOWLEDGE ABOUT THE GENOMIC TECHNOLOGY
  1. KEY ANALYTICS
    1. PORTER’S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER’S POWER
      4. SUPPLIER’S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON DIGITAL GENOME MARKET
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. KEY INVESTMENT INSIGHTS
  2. MARKET BY PRODUCT
    1. SEQUENCING AND ANALYZER INSTRUMENTS
    2. DNA/RNA ANALYSIS
    3. SEQUENCING AND ANALYSIS SOFTWARE
    4. SEQUENCING CHIPS
    5. SAMPLE PREP INSTRUMENTS
  3. MARKET BY APPLICATION
    1. DIAGNOSTICS
    2. DRUG DISCOVERY
    3. ACADEMIC RESEARCH
    4. PERSONALIZED MEDICINE
    5. AGRICULTURAL
    6. OTHER APPLICATIONS
  4. MARKET BY END-USER
    1. DIAGNOSTICS AND FORENSIC LABS
    2. ACADEMIC RESEARCH INSTITUTES
    3. HOSPITALS
    4. OTHER END-USERS
  5. GEOGRAPHICAL ANALYSIS
    1. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5. COUNTRY ANALYSIS
        1. GERMANY
        2. FRANCE
        3. UNITED KINGDOM
        4. ITALY
        5. RUSSIA
        6. BELGIUM
        7. POLAND
        8. REST OF EUROPE
  1. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2. COMPANY PROFILE
      1. ABBOTT LABORATORIES
      2. AGILENT TECHNOLOGIES INC.
      3. BECTON, DICKINSON AND COMPANY (BD)
      4. BIOMERIEUX SA
      5. BIO-RAD LABORATORIES INC
      6. HOFFMANN-LA ROCHE
      7. ILLUMINA INC
      8. INSCRIPTA
      9. OXFORD NANOPORE TECHNOLOGIES LTD
      10. PACIFIC BIOSCIENCE
      11. PERKINELMER INC
      12. QIAGEN NV
      13. REGENERON PHARMACEUTICALS
      14. THERMO FISHER SCIENTIFIC INC
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - DIGITAL GENOME

TABLE 2: EUROPE DIGITAL GENOME MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: EUROPE DIGITAL GENOME MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: EUROPE DIGITAL GENOME MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: EUROPE DIGITAL GENOME MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: EUROPE DIGITAL GENOME MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: EUROPE DIGITAL GENOME MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: EUROPE DIGITAL GENOME MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 9: EUROPE DIGITAL GENOME MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 10: LEADING PLAYERS OPERATING IN EUROPE DIGITAL GENOME MARKET

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: EUROPE DIGITAL GENOME MARKET, BY PRODUCT, IN 2020

FIGURE 6: EUROPE DIGITAL GENOME MARKET, BY SEQUENCING AND ANALYZER INSTRUMENTS, 2021-2028 (IN $ MILLION)

FIGURE 7: EUROPE DIGITAL GENOME MARKET, BY DNA/RNA ANALYSIS, 2021-2028 (IN $ MILLION)

FIGURE 8: EUROPE DIGITAL GENOME MARKET, BY SEQUENCING AND ANALYSIS SOFTWARE, 2021-2028 (IN $ MILLION)

FIGURE 9: EUROPE DIGITAL GENOME MARKET, BY SEQUENCING CHIPS, 2021-2028 (IN $ MILLION)

FIGURE 10: EUROPE DIGITAL GENOME MARKET, BY SAMPLE PREP INSTRUMENTS, 2021-2028 (IN $ MILLION)

FIGURE 11: EUROPE DIGITAL GENOME MARKET, BY APPLICATION, IN 2020

FIGURE 12: EUROPE DIGITAL GENOME MARKET, BY DIAGNOSTICS, 2021-2028 (IN $ MILLION)

FIGURE 13: EUROPE DIGITAL GENOME MARKET, BY DRUG DISCOVERY, 2021-2028 (IN $ MILLION)

FIGURE 14: EUROPE DIGITAL GENOME MARKET, BY ACADEMIC RESEARCH, 2021-2028 (IN $ MILLION)

FIGURE 15: EUROPE DIGITAL GENOME MARKET, BY PERSONALIZED MEDICINE, 2021-2028 (IN $ MILLION)

FIGURE 16: EUROPE DIGITAL GENOME MARKET, BY AGRICULTURAL, 2021-2028 (IN $ MILLION)

FIGURE 17: EUROPE DIGITAL GENOME MARKET, BY OTHER APPLICATIONS, 2021-2028 (IN $ MILLION)

FIGURE 18: EUROPE DIGITAL GENOME MARKET, BY END-USER, IN 2020

FIGURE 19: EUROPE DIGITAL GENOME MARKET, BY DIAGNOSTICS AND FORENSIC LABS, 2021-2028 (IN $ MILLION)

FIGURE 20: EUROPE DIGITAL GENOME MARKET, BY ACADEMIC RESEARCH INSTITUTES, 2021-2028 (IN $ MILLION)

FIGURE 21: EUROPE DIGITAL GENOME MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)

FIGURE 22: EUROPE DIGITAL GENOME MARKET, BY OTHER END-USERS, 2021-2028 (IN $ MILLION)

FIGURE 23: EUROPE DIGITAL GENOME MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 24: GERMANY DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

FIGURE 25: FRANCE DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

FIGURE 26: UNITED KINGDOM DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

FIGURE 27: ITALY DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

FIGURE 28: RUSSIA DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

FIGURE 29: BELGIUM DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

FIGURE 30: POLAND DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

FIGURE 31: REST OF EUROPE DIGITAL GENOME MARKET, 2021-2028 (IN $ MILLION)

Request For A Free Sample